Anti-infectives

Can cellular screening deliver?

Thomas H. Keller, Pei-Yong Shi, Qing Yin Wang

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In an era of emerging and reemerging infectious diseases, and increasing multidrug resistance, the need to identify novel therapy is imperative. Unfortunately, the recent shift of the drug discovery paradigm from cellular screening to target-based approaches has not delivered the anticipated benefits. A recent renaissance of the traditional cell-based approach, on the other hand, has yielded several clinical candidates. Three successful examples are illustrated in this review, namely spiroindolone, thiazolidinone, and diarylquinoline for the treatment of malaria, hepatitis C virus, and tuberculosis, respectively. We describe in detail their identification, mechanism of action (MoA), and common features in the chemical structures. The challenges of the cell-based approach for anti-infective drug discovery are also discussed. We propose a shift from standard libraries to synthetic natural-product-like compound collections to improve the success of phenotypic lead finding and to facilitate the validation of hits.

Original languageEnglish (US)
Pages (from-to)529-533
Number of pages5
JournalCurrent Opinion in Chemical Biology
Volume15
Issue number4
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Emerging Communicable Diseases
Drug Discovery
Diarylquinolines
Screening
Multiple Drug Resistance
Biological Products
Viruses
Hepacivirus
Malaria
Libraries
Tuberculosis
Therapeutics
Lead
Renaissance

ASJC Scopus subject areas

  • Biochemistry
  • Analytical Chemistry

Cite this

Anti-infectives : Can cellular screening deliver? / Keller, Thomas H.; Shi, Pei-Yong; Wang, Qing Yin.

In: Current Opinion in Chemical Biology, Vol. 15, No. 4, 08.2011, p. 529-533.

Research output: Contribution to journalArticle

Keller, Thomas H. ; Shi, Pei-Yong ; Wang, Qing Yin. / Anti-infectives : Can cellular screening deliver?. In: Current Opinion in Chemical Biology. 2011 ; Vol. 15, No. 4. pp. 529-533.
@article{8b28cff5017b453ebd8b15257f47aea3,
title = "Anti-infectives: Can cellular screening deliver?",
abstract = "In an era of emerging and reemerging infectious diseases, and increasing multidrug resistance, the need to identify novel therapy is imperative. Unfortunately, the recent shift of the drug discovery paradigm from cellular screening to target-based approaches has not delivered the anticipated benefits. A recent renaissance of the traditional cell-based approach, on the other hand, has yielded several clinical candidates. Three successful examples are illustrated in this review, namely spiroindolone, thiazolidinone, and diarylquinoline for the treatment of malaria, hepatitis C virus, and tuberculosis, respectively. We describe in detail their identification, mechanism of action (MoA), and common features in the chemical structures. The challenges of the cell-based approach for anti-infective drug discovery are also discussed. We propose a shift from standard libraries to synthetic natural-product-like compound collections to improve the success of phenotypic lead finding and to facilitate the validation of hits.",
author = "Keller, {Thomas H.} and Pei-Yong Shi and Wang, {Qing Yin}",
year = "2011",
month = "8",
doi = "10.1016/j.cbpa.2011.06.007",
language = "English (US)",
volume = "15",
pages = "529--533",
journal = "Current Opinion in Chemical Biology",
issn = "1367-5931",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Anti-infectives

T2 - Can cellular screening deliver?

AU - Keller, Thomas H.

AU - Shi, Pei-Yong

AU - Wang, Qing Yin

PY - 2011/8

Y1 - 2011/8

N2 - In an era of emerging and reemerging infectious diseases, and increasing multidrug resistance, the need to identify novel therapy is imperative. Unfortunately, the recent shift of the drug discovery paradigm from cellular screening to target-based approaches has not delivered the anticipated benefits. A recent renaissance of the traditional cell-based approach, on the other hand, has yielded several clinical candidates. Three successful examples are illustrated in this review, namely spiroindolone, thiazolidinone, and diarylquinoline for the treatment of malaria, hepatitis C virus, and tuberculosis, respectively. We describe in detail their identification, mechanism of action (MoA), and common features in the chemical structures. The challenges of the cell-based approach for anti-infective drug discovery are also discussed. We propose a shift from standard libraries to synthetic natural-product-like compound collections to improve the success of phenotypic lead finding and to facilitate the validation of hits.

AB - In an era of emerging and reemerging infectious diseases, and increasing multidrug resistance, the need to identify novel therapy is imperative. Unfortunately, the recent shift of the drug discovery paradigm from cellular screening to target-based approaches has not delivered the anticipated benefits. A recent renaissance of the traditional cell-based approach, on the other hand, has yielded several clinical candidates. Three successful examples are illustrated in this review, namely spiroindolone, thiazolidinone, and diarylquinoline for the treatment of malaria, hepatitis C virus, and tuberculosis, respectively. We describe in detail their identification, mechanism of action (MoA), and common features in the chemical structures. The challenges of the cell-based approach for anti-infective drug discovery are also discussed. We propose a shift from standard libraries to synthetic natural-product-like compound collections to improve the success of phenotypic lead finding and to facilitate the validation of hits.

UR - http://www.scopus.com/inward/record.url?scp=79961014405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961014405&partnerID=8YFLogxK

U2 - 10.1016/j.cbpa.2011.06.007

DO - 10.1016/j.cbpa.2011.06.007

M3 - Article

VL - 15

SP - 529

EP - 533

JO - Current Opinion in Chemical Biology

JF - Current Opinion in Chemical Biology

SN - 1367-5931

IS - 4

ER -